RAS inhibition with ACE-I or AT1R blocker prevents the down-regulation of the SCN5A and the INa [17], which can reduce the pro-arrhythmic risk in conditions with increased Ang II activity such as AF and heart failure (HF) [25]. The gene discussed is AGT; the disease is heart failure.